Migraine Without Aura
91
9
10
55
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Research Maturity
55 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.6%
6 terminated out of 91 trials
90.2%
+3.6% vs benchmark
19%
17 trials in Phase 3/4
16%
9 of 55 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 55 completed trials
Clinical Trials (91)
Migraine Attack Pain Phase Prediction Study
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Brain Connectome for Acupuncture-treated Migraine Patients
Mind Body Balance for Pediatric Migraine
A Comprehensive Digital Care Program for Migraine Management
Effectiveness and Tolerability of Eptinezumab
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Using Virtual Reality to Teach Mindfulness to People With Migraine
Trial Designs for Evaluating Migraine Treatment
Responding With Evidence and Access for Childhood Headaches
ACT Therapy for HF Migraine
App-Based Migraine Treatment: The Health enSuite Study
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)
Myotensive Extraocular Muscle Techniques Added to Manual Therapy for Migraine Without Aura
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Understanding the Pathophysiology of Migraine Pain